348 related articles for article (PubMed ID: 11342146)
1. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM
Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
4. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.
Sapra P; Allen TM
Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
6. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin.
Lundberg BB; Griffiths G; Hansen HJ
Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
9. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
[TBL] [Abstract][Full Text] [Related]
10. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo.
Lopes de Menezes DE; Pilarski LM; Belch AR; Allen TM
Biochim Biophys Acta; 2000 Jun; 1466(1-2):205-20. PubMed ID: 10825443
[TBL] [Abstract][Full Text] [Related]
12. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
Laginha KM; Moase EH; Yu N; Huang A; Allen TM
J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
[TBL] [Abstract][Full Text] [Related]
14. Targeting Stealth liposomes in a murine model of human small cell lung cancer.
Moreira JN; Gaspar R; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):167-76. PubMed ID: 11718672
[TBL] [Abstract][Full Text] [Related]
15. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
Franco MS; Roque MC; de Barros ALB; de Oliveira Silva J; Cassali GD; Oliveira MC
Biomed Pharmacother; 2019 Jan; 109():1728-1739. PubMed ID: 30551427
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
[TBL] [Abstract][Full Text] [Related]
19. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
20. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]